Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Dubois, Brunoa; * | Zaim, Mohammedb | Touchon, Jacquesc | Vellas, Brunod | Robert, Philippee | Murphy, Michael F.f | Pujadas-Navinés, Francescg | Rainer, Michaelh | Soininen, Hilkkai | Riordan, Henry J.f | Kanony-Truc, Claireb
Affiliations: [a] Institute for Memory and Alzheimer's Disease, ICM, UMR-S975, AP-HP, Pitié-Salpêtrière Hospital Group, Pierre and Marie Curie University, Paris, France | [b] Pierre Fabre Innovation, IRPF, Toulouse, France | [c] Service de Neurologie, CHU Gui de CHAULIAC, Montpellier, France | [d] Gérontopôle de Toulouse, Department of Geriatrics, CHU Toulouse, Toulouse, France | [e] Centre de recherche de ressource et de Recherche, EA CoBTek Université de Nice Sophia Antipolis, Nice, France | [f] Medical and Scientific Affairs, Worldwide Clinical Trials, King of Prussia, PA, USA | [g] Servicio de Neurología, Hospital Vall d'Hebron, Barcelona, Spain | [h] Memory Clinic, Gerontopsychiatrie, Wien, Austria | [i] Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
Correspondence: [*] Correspondence to: Pr. Bruno Dubois, Director of the « Institute for Memory and Alzheimer's Disease » (IMMA), Director of INSERM Unit “Cognition, Neuroimagery and Brain diseases” (ICM), Hôpital La Salpêtrière, 47 Bd de l'hôpital, 75013 Paris, France. Tel.: +33 (0)142167502; Fax: +33 (0)142167504; E-mail: bruno.dubois@psl.aphp.fr.
Abstract: New criteria related to prodromal Alzheimer's disease (AD) have been proposed to overcome the issue of heterogeneity of patients with mild cognitive impairment (MCI) and to better define patients in early stage AD. Only few therapeutic trials, if any, have been reported using this newly defined population. The objective of this study was to assess the clinical efficacy and safety of a novel pro-cholinergic drug (V0191) in patients with prodromal AD. Two hundred forty two (242) patients with a diagnosis of prodromal AD were randomized in an approximately 1 : 1 ratio to receive either 1500 mg V0191 or matching placebo once daily for 24 weeks. Changes in global cognitive functioning were assessed using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog; responder rate as primary efficacy measure). Standardized measures of memory, executive function, attention, functional capacity, and apathy were also obtained. Despite some interesting trends at week 12 and conversion rates favoring V0191, no statistically significant differences in cognitive function between V0191 and placebo were noted. In addition to the absence of drug efficacy on this population, several design features may have hindered this study, including insufficient powering to assess changes in cognition over time, a relatively short duration of treatment, and the lack of validated clinical trial measures designed to assess the prodromal AD population. Lessons learned in AD study design optimization, including those presented in this paper, could be valuable for further investigation with pro-cholinergic drugs such as V0191.
Keywords: Acetylcholine, Alzheimer's disease, cholinergic, drug, MCI, memory, prodromal Alzheimer's disease
DOI: 10.3233/JAD-2012-111370
Journal: Journal of Alzheimer's Disease, vol. 29, no. 3, pp. 527-535, 2012
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl